The ‘Price of Caution’ during a pandemic: MLI Commentary by David Zitner
OTTAWA, ON (August 13, 2020): The COVID-19 pandemic has exposed weaknesses in our health care systems, but to what extent remains unclear. Moreover,...
Measuring Health and Managing Health Care Routinely and in Pandemics: David Zitner for Inside Policy
In the absence of COVID testing capacity, it is important to identify the most common problems in communities and the interventions that are...
Rush to expand MAiD turns policy-making on its head: Harvey Schipper and Harry Swain in the Vancouver Sun
There is something troubling, even dangerous, about the way MAiD is evolving in Canada, and that is the absence of evidence, write Harvey...
How pandemic modelling failed policy-makers, and how to do better: MLI Commentary by Harvey Schipper
OTTAWA, ON (July 9, 2020): The existing models for epidemics, which were used to trigger lockdowns around the globe in response to COVID-19,...
COVID-19 Highlights Weaknesses in Canada’s System for New Medicines: MLI report by Rawson and Adams
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world races for new...
Don't let price controls delay access to a vaccine: Nigel Rawson and Olaf Koester in the Financial Post
Unless Ottawa guarantees the price or postpones the PMPRB revisions, manufacturers will not know whether a tendered price is compliant with the new...
Government refuses to address real cause of missing cystic fibrosis treatment in Canada: Nigel Rawson in National Newswatch
Nothing fair exists in denying Canadian cystic fibrosis patients approved and funded access to treatments that they have been waiting for throughout their...
It’s time to start out-thinking the virus: Brian Ferguson for Inside Policy
Lockdown measures were the correct decision at the time, but to focus entirely on COVID-19 cases, the exclusion of the harm being done...
COVID-19, other rare disorders and the rescue principle: Nigel Rawson and John Adams for Inside Policy
Lower ceiling prices for new medicines will make Canada less attractive as a country for new drugs and vaccines, making access to new...
Econ 101: Drug price controls shrink supply: Richard Owens in the Financial Post
Increased drug revenues enable increased research and development expenditures, which in turn result in better health and longer lives, writes Richard Owens. By...
12
